• general@orthocell.com
  • +61 8 9360 2888
Orthocell EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplir™
    • OrthoACI™
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplir™
    • OrthoACI™
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
03 Dec 2024
Orthocell Media Permalink

The Australian Financial Review | Perth’s billionaires pile into medtech Orthocell

Orthocell 3 December 2024

Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires pile into medtech Orthocell”.

Read more

02 Dec 2024
Orthocell Company News Permalink

Orthocell successfully completes US FDA 510(k) regulatory study for Remplir™

Orthocell 2 December 2024

Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating Remplir as a safe and effective biological medical device for use in the surgical repair of peripheral nerves.

Read more

02 Dec 2024
Orthocell Media Permalink

The Australian Business Review | Orthocell leaps closer to FDA approval after pivotal nerve-repair product study success

Orthocell 2 December 2024

Orthocell has been featured in The Australian Business Review, following today’s announcement that the US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints.

Read more

27 Nov 2024
Orthocell Company News Permalink

Orthocell Appoints Exclusive Distributor to Commence Sales of Remplir™ in Singapore

Orthocell 27 November 2024

Orthocell has announced that it has appointed @Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore.

Read more

14 Nov 2024
Orthocell Video Permalink

Stockhead Long Shortz | No nerves as company enters US market

Orthocell 14 November 2024

Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company’s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.

Read more

14 Nov 2024
Orthocell Video Permalink

Meet The Board | Independent Director, Dr. Ravi Thadhani

Orthocell 14 November 2024

The fourth episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring Independent Director, Dr. Ravi Thadhani.

Read more

11 Nov 2024
Orthocell Company News Permalink

Appointment of Key US Executives to Lead Remplir™ Launch

Orthocell 11 November 2024

Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025.

Read more

01 Nov 2024
Orthocell Audio Permalink

Equity Mates Podcast

Orthocell 1 November 2024

Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast.

Read more

22 Oct 2024
Orthocell Video Permalink

Meet The Board | Chairman, John Van Der Wielen

Orthocell 22 October 2024

The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.

Read more

16 Oct 2024
Orthocell Video Permalink

Executive Series | Meet The Board | Professor Fiona Wood AM

Orthocell 16 October 2024

In the second instalment of the ‘Meet The Board’ video series,  we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.

Read more

  • Recent posts

    • Orthocell Achieves a Record $2.73m in Revenue for June Quarter
    • First US Surgical Use of Remplir™ 
    • Breakthrough Study Confirms Remplir™ Superiority Over Standard US Nerve Repair Technique
    • Stockhead | Interview with Dr Ian Valerio
    • The West Australian | Biotech’s easy cell to crack American market
Previous
Next
  • © Orthocell Ltd. All rights reserved.

  • Contact Us

  • P: +61 8 9360 2888
    F: +61 8 9360 2899
    E: general@orthocell.com

  • News Updates

  • By entering your email address you are agreeing to our privacy policy.

BUILT WITH ♡ BY H^CK Orthocell EU/UK POWERED BY United Themes™
Please select the country you would like to view

Visit AU – Home

Visit Americas

Visit EU/UK

Join our mailing list

    By entering your email address you are agreeing to our privacy policy.


    Sign up to our EDM

    By entering your email address you are agreeing to our privacy policy.

    Patient expression of interest